EUVIMEDEUVIMED entdecken
Crossref

Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer

Junhui Ma, Ruixue Zhu, Meijing Li, Hui Jiao, Sijun Fan, Xiang Ma, Guangya Xiang

Acta Biomaterialia · 2025-03 · 195 · 421-435

DOI: 10.1016/j.actbio.2025.02.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025-03. Verfasst von Junhui Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: d202181670@hust.e…. Hauptthemen laut MEDLINE: Proteolysis, Doxorubicin, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis-targeting chimeras (PROTACs) have emerged as a promising strategy for targeted protein degradation and drug discovery. However, traditional PROTACs face inherent limitations and may also contribute to induce drug resistance. These challenges have driven the development of innovative strategies to overcome these obstacles. In current study, a PROTAC-DOX conjugates (PDCs) nanoassembly strategy was introduced to enhance tumor-targeting capability and overcome the drawbacks of conventional PROTACs. The designed PDC-S nanoparticles (PDC-S NPs) demonstrated potent anti-tumor activity against drug-resistant strains (IC50 = 4.7 µM) and improved in vivo efficacy (TGI = 76 %) against drug-sensitive strains, while minimizing side effects. Additionally, PDC-S NPs have great potential in tumor immunotherapy. This study provides a novel and promising strategy for the development of PROTAC-Drug Conjugates (PDCs). STATEMENT OF SIGNIFICANCE: We developed a PROTAC-DOX conjugates (PDCs) nanoassembly strategy to address the limitations of traditional PROTACs, such as poor solubility, low targeting specificity, and drug resistance. PDC-S NPs were constructed via self-assembly, which simplified preparation and minimized the toxicity typically associated with carrier-assisted delivery systems. The PDC-S NPs showed improved aqueous solubility and cellular uptake, resulting in efficient EGFR degradation in HCC827 cells. In vivo, PDC-S NPs accumulated at tumor sites via the EPR effect, resulting in enhanced anti-tumor potency with reduced side effects. Furthermore, PDC-S NPs induced immunogenic cell death (ICD) and suppressed PD-L1 and VEGF expression, highlighting great potential in tumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisDoxorubicinCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsNanoparticlesProtein Kinase InhibitorsHumansCell Line, TumorAnimalsErbB ReceptorsMiceMice, NudeMice, Inbred BALB C

Stichwörter der Autor:innen

EGFREGFR-TKIsPROTAC-SS-DOXSensitive and resistant NSCLCsTumor immunotherapy

Substanzen

DoxorubicinErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: d202181670@hust.edu.cn.
  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: zrxue99@163.com.
  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: lmj13476043810@163.com.
  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: jiaoh412@163.com.
  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: 931467586@qq.com.
  • School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; School of Pharmacy, Tongren Polytechnic College, Tongren, Guizhou 554300, China. Electronic address: xiangm…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ma, J., Zhu, R., Li, M., Jiao, H., Fan, S., Ma, X., & Xiang, G. (2025). Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer. Acta Biomaterialia, 195, 421-435. https://doi.org/10.1016/j.actbio.2025.02.012

Vancouver

Ma J, Zhu R, Li M, Jiao H, Fan S, Ma X, et al. Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer. Acta Biomaterialia. 2025;195:421-435. doi:10.1016/j.actbio.2025.02.012

BibTeX
@article{Ma2025,
  author = {Ma, Junhui and Zhu, Ruixue and Li, Meijing and Jiao, Hui and Fan, Sijun and Ma, Xiang and Xiang, Guangya},
  title = {Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer},
  journal = {Acta Biomaterialia},
  year = {2025},
  volume = {195},
  pages = {421--435},
  doi = {10.1016/j.actbio.2025.02.012}
}
Kostenlos starten →